ArticleScientific reports2020
Rosmarinic Acid Exhibits Anticancer Effects via MARK4 Inhibition.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 158 citations in OpenAlex.
- Rosmarinic acid inhibits norepinephrine-induced metastatic capacity of triple negative breast cancer cells by Src kinase inactivation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- In Vitro Cytotoxic Activity ofMolecules (Basel, Switzerland) · 2026Article
- Current State of Knowledge of the Anticancer Properties of Polyphenolic Compounds from Garlic (Molecules (Basel, Switzerland) · 2026Review
- Investigating the Cytotoxic Potential of Omphalodes cappadocica (Willd.) DC. on Breast Cancer Cells by Phytochemical-Based Molecular Docking Studies: A Comparative Study of Aerial Parts and Roots.Chemistry & biodiversity · 2026Article
- Apigenin-mediated MARK4 inhibition: a novel approach in advancing Alzheimer's disease therapeutics.Molecular diversity · 2025Article
- Targeting cancer metabolism through p-cresol mediated Inhibition of pyruvate dehydrogenase kinase 3 in lung cancer.Scientific reports · 2025Article
- The antioxidant potential of bacoside and its derivatives in Alzheimer's disease: The molecular mechanistic paths and therapeutic prospects.Toxicology reports · 2025Review
- Updated Review on Natural Polyphenols: Molecular Mechanisms, Biological Effects, and Clinical Applications for Cancer Management.Biomolecules · 2025Review
- Experimental and theoretical studies on structural changes in the microtubule affinity-regulating kinase 4 (MARK4) protein induced byFrontiers in medicine · 2025Article
- Exploring PDK3 inhibition in lung cancer through drug repurposing for potential therapeutic interventions.Scientific reports · 2024Article
- In Vitro Anticancer Effects of Aqueous Leaf Extract fromLife (Basel, Switzerland) · 2024Article
- Rosmarinic Acid: A Potential Therapeutic Agent in Gastrointestinal Cancer Management-A Review.International journal of molecular sciences · 2024Review
- The Role of Rosmarinic Acid in Cancer Prevention and Therapy: Mechanisms of Antioxidant and Anticancer Activity.Antioxidants (Basel, Switzerland) · 2024Review
- Metabolites Obtained from Boraginaceae Plants as Potential Cosmetic Ingredients-A Review.Molecules (Basel, Switzerland) · 2024Review
- Double-Edged Sword Effect of Diet and Nutrition on Carcinogenic Molecular Pathways in Breast Cancer.International journal of molecular sciences · 2024Review
- Harnessing the power of Arctium lappa root: a review of its pharmacological properties and therapeutic applications.Natural products and bioprospecting · 2024Review
- Article
- Chemopreventive Agents from Nature: A Review of Apigenin, Rosmarinic Acid, and Thymoquinone.Current issues in molecular biology · 2024Review
- Design, synthesis, molecular docking and anti-proliferative activity of novel phenothiazine containing imidazo[1,2-RSC medicinal chemistry · 2024Article
- Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microtubule affinity regulating kinase (MARK4) is a potential drug target for different types of cancer as it controls the early step of cell division. In this study, we have screened a series of natural compounds and finally identified rosmarinic acid (RA) as a potential inhibitor of MARK4. Molecular docking and 500 ns all-atom simulation studies suggested that RA binds to the active site pocket of MARK4, forming enough number of non-covalent interactions with critical residues and MARK4-RA complex is stable throughout the simulation trajectory. RA shows an excellent binding affinity to the MARK4 with a binding constant (K) of 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.